Healthcare Financial News

KKR has announced its acquisition of a significant minority stake in Infinx Services, the leading healthcare revenue cycle solutions provider. Through this investment, KKR will leverage its extensive experience in the global healthcare and technology sectors to accelerate Infinx’s growth, expand the company’s network, and support bolt-on acquisitions, stated a company release. Norwest Venture Partners, an existing shareholder, also participated in the transaction. Co-founded in 2012 by Sandeep Tandon and Jaideep Tandon, Infinx is a provider of data-driven revenue cycle management solutions for the healthcare sector, with a particular focus on the US market. Infinx’s Healthcare Revenue Cloud platform supports end-to-end revenue cycle business functions utilizing AI, automation, payer integration, and workforce management.

Animal healthcare solutions firm Ajooni Biotech on Tuesday opened its rights issue with an aim to raise Rs 43.81 crore from existing shareholders. Ajooni Biotech will offer 8,76,13,721 fully paid-up equity shares of the face value of Rs 2 each at a price of Rs 5 per equity share aggregating to Rs 43.81 crore, the company said in a statement. The issue will close on May 31.

F&O ban list: Thirteen stocks have been banned for trade on Tuesday, May 21, 2024, under the futures and options (F&O) segment by the National Stock Exchange (NSE). The securities have been put on ban under the F&O segment as they crossed 95% of the market-wide position limit (MWPL), according to the NSE. However, these stocks will be available for trading in the cash market.

Mint. “However, the increase in the number of people who can afford and the change in consumer demand towards quality has prompted our investment thesis to evolve." Peak XV (formerly Sequoia India and Southeast Asia) recently invested $12 million in Mokobara. Its consumer portfolio includes petcare startup Heads Up For Tails, nutraceuticals seller Healthkart, and home improvement firm HomeLane.

KKR is looking to acquire a minority stake in the Tandon Group-owned healthcare BPO Infinx Healthcare. The global private equity major is likely to invest about $150 million, or Rs 1,250 crore, to acquire about 26% stake in Infinx, two people aware of the development told ET. «We expect this sector (healthcare BPO) to continue growing in India, driven by global demand, and believe that Infinx is well placed to meet this gap through its tech-enabled solutions,» Akshay Tanna, partner and head of India private equity at KKR, told ET. «We will draw on our local knowledge and healthcare expertise to support Infinx's growth and build a healthcare platform, including through organic and inorganic growth strategies.»

reform plan for the Central Government Health Scheme (CGHS) ahead of the new government taking charge next month. It is learnt that the cabinet secretary has been holding rounds of discussions with stakeholder ministries and departments over the last few weeks to address various problems currently ailing the CGHS — from flagging partnership with major private hospitals amid pending dues to taxing referral system and shortage of doctors and healthcare staff to the simmering concern on linkage of CGHS cards with the digitalised Ayushman Bharat Health Account (ABHA) cards. A committee of secretaries is learnt to be looking into the issues.

FSN E-Commerce Ventures (Nykaa), ONGC, NTPC, Hindalco, Hindustan Copper, JK Lakshmi Cement, ITC, Sun Pharmaceuticals, and others. Also read: Week Ahead: US Fed chair speech, Q4 results, FII activity, global cues among key market triggers next week ONGC, Indian Railway Finance Corporation (IRFC), Bharat Electronics (BEL), Oil India, SAIL, Deepak Nitrite, Whirlpool of India, City Union Bank, Redtape, Power Mech Projects, Triveni Engineering & Industries, Chemplast Sanmar, India Cements, KRBL, Nesco, Rolex Rings, VRL Logistics.

Singapore is experiencing a new wave of COVID-19, with authorities recording over 25,900 cases from May 5 to 11. Health Minister Ong Ye Kung advised the public to wear masks again on Saturday.

Singapore is seeing a new COVID-19 wave as the authorities recorded more than 25,900 cases from May 5 to 11 even as Health Minister Ong Ye Kung on Saturday advised the wearing of masks again. «We are at the beginning part of the wave where it is steadily rising,» said Ong. «So, I would say the wave should peak in the next two to four weeks, which means between mid- and end of June,» The Straits Times newspaper quoted the minister as saying. The Ministry of Health (MOH) said the estimated number of COVID-19 cases in the week of May 5 to 11 rose to 25,900 cases, compared with 13,700 cases in the previous week.

₹16.5 - 17.5 lakh crore in FY28. The growth is likely to be driven by favourable macroeconomic factors such as healthcare infrastructure and a structural shift towards an organised market. The industry saw some growth impact during COVID in FY21 as it grew 10% YoY to ₹8 lakh crore and subsequently a bounce-back in FY22, growing 15% YoY to ₹9.2 lakh crore, and normalized growth in FY23 at 15% YoY to ₹10 lakh crore.

One of the more popular tax credits, claimed by more than five million Canadians annually, is the medical expense tax credit (METC), which provides tax relief for qualifying above-average medical or disability-related expenses incurred by individuals on behalf of themselves, a spouse or common-law partner, or a dependent relative.

GSK has raised 1.25 billion pounds ($1.52 billion) from a sale of its remaining stake in consumer healthcare company Haleon to institutional investors. The sale will allow GSK to sharpen its focus on vaccines, cancer and infectious diseases, which are part of CEO Emma Walmsley's plans to boost earnings at the drugmaker.

At least once a day, a group of American doctors and nurses stranded in Gaza get word that they might be able to leave the enclave. They have waited all week, and that moment hasn’t come. “We’ve come to terms with the fact that we don’t know when we’re leaving," said Dr.

Max Healthcare Institute Ltd. fell 0.35 per cent to Rs 845.25 in Friday's session as of 01:58PM (IST) even as the equity benchmark Sensex traded 286.34 points higher at 73950.06. Earlier in the day, the stock witnessed a gap up start to the session. The stock quoted a 52-week high price of Rs 909.0 and a 52-week low of Rs 505.35 on NSE. Around 9449 shares changed hands on the counter till 01:58PM (IST).

Linde India shares surged by 5%, reaching an all-time high of ₹9,431 per share in today's intraday trade, driven by heavy trading volumes. This latest rally marks a stellar gain of 55.23% over the past six months and an astounding 140% over the course of a year. The stock has consistently built on its gains year after year.

Indian stock market. Prabhudas Lilladher, a leading brokerage, foresees sectors like FMCG, Auto, Healthcare, IT Services, Private Banks, and Capital Goods as a 'perfect hedge' against the election results, slated for 4th June 2024.

Vaccines manufacturer Serum Institute of India (SII) on Friday said it is acquiring 20 per cent stake in IntegriMedical, to advance needle-free injection system technology. IntegriMedical has developed a US patented needle-free Injection System (N-FIS) that utilises high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs, Serum Institute of India (SII) said in a statement. The company, however, did not disclose the financial details of the transaction. The innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a stress-free experience.

More couples are choosing to secure their financial future from unwarranted healthcare expenses by opting for comprehensive maternity coverage as they plan to welcome a baby into their family. Growing awareness of rising healthcare costs among wannabe parents has led to an 80 per cent YoY increase in maternity plans in FY24, according to PolicyBazaar data.

The biopharmaceutical industry has been evolving rapidly. During the turbulent period spanning 2019 to 2021, amid the upheaval caused by the covid pandemic, it emerged as a focal point of global discourse. Biopharmaceuticals are drugs and therapies synthesized from living organisms, which includes vaccines, biologics, biosimilars and evolving therapies like cell and gene therapies.

“Phases of strong economic growth have seen healthy stock returns in the mid cap and small cap categories,” says Hitesh Zaveri, SVP & Head, Listed Equity Alternatives, Axis AMC. In an interview with ETMarkets, Zaveri who manages more than Rs 1600 cr said: “The Indian economy is currently in a multi-year high growth phase with growth being broad-based across sectors,”. Edited excerpts: Please take us through the investment philosophy of Axis Brand Equity Portfolio and Axis Core & Satellite portfolio? Hitesh Zaveri: Axis Brand Equity and Core & Satellite are both multi-cap strategies. Axis Brand Equity Portfolio invests in companies where Brands are an important factor for their customers/ clients.

The drug maker reported net profit of Rs 294 crore in the corresponding period of previous year.